261 related articles for article (PubMed ID: 20034874)
21. Targeting the epidermal growth factor receptor in colorectal carcinoma.
Kurtin SE
Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
[TBL] [Abstract][Full Text] [Related]
22. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
Sinclair R
Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509
[TBL] [Abstract][Full Text] [Related]
23. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
Gencoglan G; Ceylan C
Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
[TBL] [Abstract][Full Text] [Related]
24. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
Garden BC; Wu S; Lacouture ME
J Am Acad Dermatol; 2012 Sep; 67(3):400-8. PubMed ID: 22088429
[TBL] [Abstract][Full Text] [Related]
25. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Reimer G; Brudler O; Heinrich B; Bangerter M
MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
[No Abstract] [Full Text] [Related]
26. [Acneiform skin eruption in patients with metastatic colorectal carcinoma].
Gethöffer K; Schneider LA; Peters T; Weber L; Scharffetter-Kochanek K
Hautarzt; 2006 Jul; 57(7):628-31. PubMed ID: 16034631
[No Abstract] [Full Text] [Related]
27. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
28. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.
Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J
J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385
[TBL] [Abstract][Full Text] [Related]
29. EGFR inhibitor-associated acneiform folliculitis: assessment and management.
Duvic M
Am J Clin Dermatol; 2008; 9(5):285-94. PubMed ID: 18717603
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor inhibitor-related folliculitis.
Tangri N; Al Hammadi A; Gerstein W
Dermatitis; 2007 Sep; 18(3):178-9. PubMed ID: 17725926
[No Abstract] [Full Text] [Related]
31. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
32. Clinical management of cutaneous toxicity of anti-EGFR agents.
Monti M; Motta S
Int J Biol Markers; 2007; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
34. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.
Perez-Soler R; Zou Y; Li T; Ling YH
Clin Cancer Res; 2011 Nov; 17(21):6766-77. PubMed ID: 21914790
[TBL] [Abstract][Full Text] [Related]
35. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
36. Malassezia folliculitis presented as acneiform eruption after cetuximab administration.
Cholongitas E; Pipili C; Ioannidou D
J Drugs Dermatol; 2009 Mar; 8(3):274-5. PubMed ID: 19271376
[TBL] [Abstract][Full Text] [Related]
37. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
38. Re: Cetuximab therapy and symptomatic hypomagnesemia.
Altundag K; Altundag O; Baptista MZ; Turen S; Atik MA
J Natl Cancer Inst; 2005 Dec; 97(23):1791-2. PubMed ID: 16333039
[No Abstract] [Full Text] [Related]
39. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
Busam KJ; Capodieci P; Motzer R; Kiehn T; Phelan D; Halpern AC
Br J Dermatol; 2001 Jun; 144(6):1169-76. PubMed ID: 11422037
[TBL] [Abstract][Full Text] [Related]
40. Images in clinical medicine. Cetuximab-associated acneiform eruption.
Moss JE; Burtness B
N Engl J Med; 2005 Nov; 353(19):e17. PubMed ID: 16282170
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
